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This study was carried out to investigate the early changes in 
erythropoietin (EPO) formation in humans in response to 
hypoxia. Six volunteers were exposed to simulated altitudes of 
3,000 and 4,000 m in a decompression chamber for 5.5 h. EPO 
was measured by radioimmunoassay in serum samples with- 
drawn every 30 min during altitude exposure and also in two 
subjects after termination of hypoxia (4,000 m). EPO levels 
during hypoxia were significantly elevated after 114 and 84 min 
(3,000 and 4,000 m), rising thereafter continuously for the 
period investigated. Mean values increased from 16.0 to 22.5 
mu/ml (3,000 m) and from 16.7 to 28.0 mu/ml (4,000 m). This 
rise in EPO levels corresponds to 1.8-fold (3,000 m) and 3.0- 
fold (4,000 m) increases in the calculated production rate of the 
hormone. After termination of hypoxia, EPO levels continued 
to rise for ~1.5 h and after 3 h declined exponentially with an 
average half-life time of 5.2 h. 
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THE ADJUSTMENT OF THE erythrocyte mass to the avail- 
ability of 02 in the mammalian organism is brought about 
by renal secretion of erythropoietin (EPO). However, the 
regulation of renal EPO production is not completely 
understood. Present knowledge is mainly based on ex- 
periments in laboratory animals. Direct data related to 
the regulation of EPO production in humans are confined 
to two observations. First, it has been shown that in 
anemias serum EPO levels are inversely correlated with 
the hematocrit (5,7,9), and, second, it was demonstrated 
that a sojourn at high altitude increases EPO concentra- 
tions in blood and urine (1, 3, 8, 12-14, 17). However, 
when subjects travel to high altitude (1, 3,8, 12, 14), the 
interval required for ascent does not allow the precise 
study of early increase in EPO formation, because the 
onset of hypoxia is gradual and not clearly defined. 
During mountaineering expeditions (1, 12) additional 
factors, e.g., physical exercise, may also influence EPO 
formation in an unpredictable manner. Furthermore, 
with the exception of one study (12), in previous inves- 
tigations in humans only bioassays for EPO that indicate 
a change in the serum EPO level at least threefold above 
the normal value were available. 
The present study was therefore carried out to show a 
more definitive association between hypoxia and EPO 
formation in humans. We measured serum EPO levels 
with a sensitive radioimmunoassay in healthy volunteers 
exposed to simulated altitudes of 3,000 (9,840 ft) and 
4,000 m (13,120 ft) under controlled conditions in a 
decompression chamber. The changes in serum EPO 
levels after acute onset and after termination of hypoxia, 
as well as the relationship between alveolar partial pres- 
sure of 02 and EPO formation were determined. 
SUBJECTSANDMETHODS 
Subjects. Six male volunteers (24-39 yr) participated 
in the study after being informed about the aim of the 
investigation and the experimental protocol. All partici- 
pants were healthy and free from any hematologic, res- 
piratory, or renal disorder. 
ProtocoZ. Two or three subjects were exposed at one 
time to simulated altitude in a decompression chamber 
for 5.5 h. Each subject was given one exposure to an 
altitude of 3,000 m (9,840 ft) and one exposure to an 
altitude of 4,000 m (13,120 ft). The period between 
altitude exposures of the same individual was at least 24 
days. Atmospheric pressure was reduced from 720 Torr 
(base-line value, 430 m above sea level) to 520 and 460 
Torr (3,000 and 4,000 m above sea level) within 30 min. 
The ascent was interrupted for 15 min at 600 Torr (2,000 
m above sea level). During the sojourn in the hypobaric 
chamber subjects remained seated throughout the whole 
period of investigation. From each subject, 2 ml of venous 
blood were withdrawn via an indwelling cannula in the 
cubital vein 1 h before, every 30 min during, and imme- 
diately after the hypoxic exposure. Before each blood 
sampling alveolar 02 and CO2 tensions were determined 
and blood pressure and heart rate measured. In two 
subjects, blood samples were taken for an additional 6 h 
after the completion of the hypoxic exposure to 4,000 m. 
Measurement of alveolar 02 and CO2 tensions. 02 and 
COz tensions (Pop and Pco~) were measured by mass 
spectrometry in the end-expiratory respiratory gas by 
means of an on-line computerized analysis system (2). 
Measurement of EPO. EPO was estimated in serum of 
the blood samples by radioimmunoassay. The assay is 
based on a rabbit antiserum against pure recombinant 
human EPO and ‘?-labeled recombinant human EPO, 
used as tracer. Assay procedure was exactly as described 
(6), with the exception that the antiserum was further 
diluted (l:lOO,OOO instead of 1:60,000) to increase sensi- 
tivity of the assay. In brief, 100 ~1 of antiserum diluted 
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in phosphate-buffered saline (PBS) and 20 ~1 of 30% 
bovine serum albumin in PBS were incubated with 100 
~1 of standard solutions (Second International Reference 
Preparation for EPO, World Health Organization) or 
100 ~1 of serum samples for 24 h (4°C). Diluted 1251- 
labeled EPO (100 ~1, 8 x lo-l1 mol/l) (Amersham Inter- 
national, Amersham, UK) was then added, and samples 
were incubated for another 24 h (4°C). Separation of 
bound vs. free ligand was carried out by means of a 
second antibody technique: 100 ~1 of goat anti-rabbit y- 
globulin (Calbiochem Biochemistry AG, Lucerne, Swit- 
zerland) and 100 ~1 of rabbit y-globulin (0.03 mg) were 
added for 4 h; samples were then centrifuged, the super- 
natant was aspirated, and the pellet was counted for 1251 
radioactivity. Data were expressed as percent binding in 
the absence of unlabeled EPO (-35% of the radioactivity 
added), and calculations of unknowns were performed 
on the basis of a standard log dose-response curve derived 
by the spline function method (LKB Instruments Wallac 
Compu Gamma RIA program 1282-114). Samples were 
analyzed in duplicate, and all samples from individuals 
exposed simultaneously to hypoxia were analyzed in 
sequence with the use of the same assay to minimize the 
effect of interassay variation. The interassay coefficient 
of variation was 6.7% [(51 estimations of a sample con- 
taining 44.2 t 3.0 (SD) mU EPO/ml)]. 
Estimation of production rates of EPO. Relative in- 
creases of the production rate of EPO were calculated 
from serum EPO values according to the equation PRt + 
P& = (AEPO, + ln2 + tl,2 X EPOJ + (ln2 + tlh X EPOo) 
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FIG. 1. Time course of alveolar Pop and alveolar PCO~ (means k 
SE, n = 6) under exposure to hypobaric hypoxia. 
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FIG. 2. Changes in heart rate and mean arterial blood pressure 
[(systolic pressure + 2 x diastolic pressure) + 31 under exposure to 
hypobaric hypoxia (means k SE, n = 6). 
where EPOo and EPOt are the basal serum level and the 
serum level at the end of hypoxic exposure and P& and 
PRt are the respective production rates of the hormone. 
The half-life time ( tl,J of EPO was assumed to be 5.2 h, 
as estimated from the disappearance rate of EPO after 
termination of hypoxia. 
Statistics. Levels of significance were calculated using 
Student’s paired t test. P < 0.05 was considered statis- 
tically significant. 
RESULTS 
Figure 1 shows the time course of the mean alveolar 
POT (PAN,) and alveolar PCO~ (PACT,) tensions for the six 
subjects during exposure to simulated altitudes of 3,000 
and 4,000 m. The mean PAN, after arrival at final altitude 
was 60.9 Torr at 3,000 m and 48.6 Torr at 4,000 m. The 
mean PACT, was 38.0 Torr at 3,000 m and 33.6 Torr at 
4,000 m (P < 0.001 vs. base-line values). 
Heart rate and mean arterial blood pressure [(systolic 
pressure + 2 x diastolic pressure) + 31 during hypoxic 
exposure are illustrated in Fig. 2. At both altitudes mean 
arterial blood pressure declined after onset of hypoxia. 
However, at the end of hypoxic exposure it had returned 
to values not significantly different from base line (P > 
0.05). Heart rate increased at both altitudes with increas- 
ing hypoxia and remained elevated during the sojourn 
[mean heart rate between 3 and 5.5 h after arrival at 
final altitude 6.2 (3,000 m) and 17.8 beats/min (4,000 m) 
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FIG. 3. Time course of serum erythropoietin (EPO) levels as meas- 
ured by radioimmunoassay in response to hypobaric hypoxia (means k 
SE, n = 6). * P < 0.05. 
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FIG. 4. Serum erythropoietin (EPO) values (log scale) after termi- 
nation of hypobaric hypoxia (4,000 m) in 2 subjects. 
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FIG. 5. Relationship between alveolar POT and relative changes in 
the production rate of erythropoietin (EPO) (means k SE, n = 6). 
Production rates were calculated from increases in serum EPO values, 
assuming a mean half-life time for EPO of 5.2 h. 
above base-line value; P c 0.05 and P c 0.01, respec- 
tively]. 
The time course of serum EPO levels in response to 
the two different hypoxic stimuli is depicted in Fig. 3. 
The first significant increase above the mean of the two 
base-line values was found at 3,000 m after 114 min (P 
c 0.05) and at 4,000 m after 84 min (P < 0.05). There- 
after, EPO levels increased continuously for the period 
investigated. At 4,000 m this increase was linear to the 
end of the hypoxic exposure, whereas at 3,000 m, the 
slope of the serum values tended to flatten after ~4 h. 
After the termination of hypoxia (4,000 m) EPO levels 
were estimated for up to 6 h in two of the subjects. The 
values are shown in Fig. 4. EPO levels continued to rise 
for ~1.5 h after normoxia was restored and started to 
decline after -3 h. In both subjects EPO values fitted 
single exponential regression curves during the declining 
phase (log y = -0.064~ + 2.079, r = -0.98 for subject 1 
and logy = 0.054x + 1.941, r = -1.00 for subject 2). Half- 
life times of disappearance resulting from these slopes 
were 4.7 h in subject 1 and 5.6 h in subject 2. 
DISCUSSION 
The present study was carried out to investigate EPO 
formation in humans in the early phase of hypoxic ex- 
posure. Elevated EPO concentrations have been de- 
scribed in urine (3,8) and blood (1, 12-14, 17) within 24 
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h after the onset of hypoxia. The earliest increases were 
reported by Siri et al. (17) and Miller et al. (13), who, 
after exposing human volunteers to simulated altitudes 
of 4,500 or 5,000 m, detected EPO in serum after 12 h by 
means of a bioassay. With a sensitive radioimmunoassay 
we were able to identify the first significant increase of 
serum EPO levels after -1.5 h and a subsequent linear 
rise in EPO concentrations (Fig. 3). This time course of 
EPO values in humans is in accord with previous findings 
in rodents (4,15, 16). In particular, the time lag between 
onset of hypoxia and elevation of serum EPO values is 
very similar in humans and rodents. This interval sug- 
gests that no stores of EPO are available for rapid release 
into the circulation. In rats, this has been supported by 
the finding that significant amounts of EPO were only 
extractable from kidney tissue during hypoxia and not 
in normoxic animals (10, 11). On the basis of the similar 
temporal relationships it may be inferred that informa- 
tion obtainable only in animals during the delay period 
also applies to humans. So far mRNA for EPO has been 
demonstrated in rat kidneys after 1 h of hypoxia (16), 
and it has also been demonstrated in rats that EPO levels 
in kidney tissue precede the rise in serum levels for -30 
min (4, 16). 
The time required for transducing the stimulating 
signal for EPO production into a rise of serum EPO 
values is further reflected by the ongoing increase in 
EPO levels after termination of hypoxia (Fig. 4). From 
the slope of the subsequent decline in EPO values, a 
half-life time of disappearance of -5.2 h was estimated 
from the observations in two subjects. This period is 
longer than that previously reported in mice (3.25 h) (1). 
Assuming an EPO half-life time of 5.2 h for all subjects 
allows an estimation of the individual increase of renal 
production rates of EPO from the increase of serum EPO 
values. This quantity more directly reflects the extent of 
stimulation of EPO formation than serum values alone. 
At 3,000 m, renal production rates for EPO increased 
U-fold and at 4,000 m they increased 3.0-fold. The 
relationship between the production rate of the hormone 
and PAN, as an indicator for the 02 supply of the body is 
depicted in Fig. 5. It appears from this relationship that 
the regulation of EPO formation is rather conservative 
when 02 supply is only slightly reduced and, on the other 
hand, EPO production is strikingly enhanced when O2 
tensions, potentially harmful for vital functions of the 
organism are approached. 
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